Patents by Inventor Christopher Norbert Johnson

Christopher Norbert Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9464071
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: October 11, 2016
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Gordon Saxty, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Christopher Charles Frederick Hamlett, Christopher Norbert Johnson, Steven John Woodhead, Michael Reader, David Charles Rees, Laurence Anne Mevellec, Patrick René Angibaud, Eddy Jean Edgard Freyne, Tom Cornelis Hortense Govaerts, Johan Erwin Edmond Weerts, Timothy Pietro Suren Perera, Ronaldus Arnodus Hendrika Joseph Gilissen, Berthold Wroblowski, Jean Fernand Armand Lacrampe, Alexandra Papanikos, Olivier Alexis Georges Querolle, Elisabeth Thérèse Jeanne Pasquier, Isabelle Noëlle Constance Pilatte, Pascal Ghislain André Bonnet, Werner Constant Johan Embrechts, Rhalid Akkari, Lieven Meerpoel
  • Publication number: 20150353537
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: October 18, 2013
    Publication date: December 10, 2015
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni CHESSARI, Christopher Norbert JOHNSON, Lee William PAGE, Ildiko Maria BUCK, James Edward Harvey DAY, Steven HOWARD, Gordon SAXTY, Christopher William MURRAY
  • Publication number: 20150291586
    Abstract: The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2a, R2b, R3a, R3b, R5, R6, R7, R8, R9, p and E are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: March 20, 2015
    Publication date: October 15, 2015
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Alison Jo-Anne WOOLFORD, Steven HOWARD, Ildiko Maria BUCK, Gianni CHESSARI, Christopher Norbert JOHNSON, Emiliano TAMANINI, James Edward Harvey DAY, Elisabetta CHIARPARIN, Thomas Daniel HEIGHTMAN, Martyn FREDERICKSON, Charlotte Mary GRIFFITHS-JONES
  • Publication number: 20150266873
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: October 18, 2013
    Publication date: September 24, 2015
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni Chessari, Christopher Norbert Johnson, Lee William Page, Alessia Millemaggi, Steven Howard, Gordon Saxty, Thomas Daniel Heightman
  • Publication number: 20150259359
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: October 18, 2013
    Publication date: September 17, 2015
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni Chessari, Christopher Norbert Johnson, Lee William Page, Ildiko Maria Buck, James Edward Harvey Day, Steven Howard, Gordon Saxty, Christopher William Murray, Anna Hopkins
  • Patent number: 9018214
    Abstract: The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2a, R2b, R3a, R3b, R5, R6, R7, R8, R9, p and E are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: April 28, 2015
    Assignee: Astex Therapeutics Limited
    Inventors: Alison Jo-Anne Woolford, Steven Howard, Ildiko Maria Buck, Gianni Chessari, Christopher Norbert Johnson, Emiliano Tamanini, James Edward Harvey Day, Elisabetta Chiarparin, Thomas Daniel Heightman, Martyn Frederickson, Charlotte Mary Griffiths-Jones
  • Publication number: 20150105368
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: October 2, 2014
    Publication date: April 16, 2015
    Applicant: ASTEX THERAPEUTICS LTD
    Inventors: Gordon SAXTY, Christopher William MURRAY, Valerio BERDINI, Gilbert Ebai BESONG, Christopher Charles Frederick HAMLETT, Christopher Norbert JOHNSON, Steven John WOODHEAD, Michael READER, David Charles REES, Laurence Anne MEVELLEC, Patrick René ANGIBAUD, Eddy Jean Edgard FREYNE, Tom Cornelis Hortense GOVAERTS, Johan Erwin Edmond WEERTS, Timothy Pietro Suren PERERA, Ronaldus Arnodus Hendrika Joseph GILISSEN, Berthold WROBLOWSKI, Jean Fernand Armand LACRAMPE, Alexandra PAPANIKOS, Oliver Alexis Georges QUEROLLE, Elisabeth Thérèse Jeanne PASQUIER, Isabelle Noëlle Constance PILATTE, Pascal Ghislain André BONNET, Werner Constant Johan EMBRECHTS, Rhalid AKKARI, Lieven MEERPOEL
  • Patent number: 8895601
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: November 25, 2014
    Assignee: Astex Therapeutics Ltd
    Inventors: Gordon Saxty, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Christopher Charles Frederick Hamlett, Christopher Norbert Johnson, Steven John Woodhead, David Charles Rees, Laurence Anne Mevellec, Patrick René Angibaud, Eddy Jean Edgard Freyne, Timothy Pietro Suren Perera, Ronaldus Arnodus Hendrika Joseph Gilissen, Berthold Wroblowski, Jean Fernand Armand Lacrampe, Alexandra Papanikos, Oliver Alexis Georges Querolle, Elisabeth Thérèse Jeanne Pasquier, Isabelle Noëlle Constance Pilatte, Pascal Ghislain André Bonnet, Werner Constant Johan Embrechts, Rhalid Akkari, Lieven Meerpoel
  • Publication number: 20140179666
    Abstract: The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2a, R2b, R3a, R3b, R5, R6, R7, R8, R9, p and E are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: April 20, 2012
    Publication date: June 26, 2014
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Alison Jo-Anne Woolford, Steven Howard, Ildiko Maria Buck, Gianni Chessari, Christopher Norbert Johnson, Emiliano Tamanini, James Edward Harvey Day, Elisabetta Chiarparin, Thomas Daniel Heightman, Martyn Frederickson, Charlotte Mary Griffiths-Jones
  • Publication number: 20130317041
    Abstract: The present invention relates to benzylpiperazine derivatives such as compounds of formula (I), which have activity as agonists of the GPR38 receptor and the use of such compounds or pharmaceutical compositions thereof in the preparation of medicaments suitable for the treatment of gastrointestinal disorders.
    Type: Application
    Filed: August 5, 2013
    Publication date: November 28, 2013
    Applicant: Glaxo Group Limited
    Inventors: Christopher Norbert JOHNSON, David Timothy MacPherson, Steven James Stanway, Geoffrey Stemp, Mervin Thompson, Susan Marie Westaway
  • Publication number: 20130261185
    Abstract: A compound of formula (I) or a pharmaceutically acceptable derivative thereof, wherein, R1, R2, R3, R4, R5, m, n and X are as defined in the specification; a process for preparing such compounds; a pharmaceutical composition comprising such compounds; and the use of such compounds in medicine.
    Type: Application
    Filed: October 8, 2012
    Publication date: October 3, 2013
    Applicant: Glaxo Group Limited
    Inventors: Alessandra Gaiba, Mark Patrick Healy, Christopher Norbert Johnson, Susan Roomans, Steven James Stanway, Martin Edward Swarbrick
  • Patent number: 8536182
    Abstract: The present invention relates to novel benzylpiperazine derivatives such as compounds of formula (I), which have activity as agonists of the GPR38 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of gastrointestinal disorders.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: September 17, 2013
    Assignee: Glaxo Group Limited
    Inventors: Christopher Norbert Johnson, David Timothy Macpherson, Steven James Stanway, Geoffrey Stemp, Mervyn Thompson, Susan Marie Westaway
  • Publication number: 20130072457
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: April 28, 2011
    Publication date: March 21, 2013
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Gordon Saxty, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Christopher Charles Frederick Hamlett, Christopher Norbert Johnson, Steven John Woodhead, Michael Reader, David Charles Rees, Laurence Anne Mevellec, Patrick René Angibaud, Eddy Jean Edgard Freyne, Tom Cornelis Hortense Govaerts, Johan Erwin Edmond Weerts, Timothy Pietro Suren Perera, Ronaldus Arnodus Hendrika Joseph Gilissen, Berthold Wroblowski, Jean Fernand Armand Lacrampe, Alexandra Papanikos, Oliver Alexis Georges Querolle, Elisabeth Thérèse Jeanne Pasquier, Isabelle Noëlle Constance Pilatte, Pascal Ghislain André Bonnet, Werner Constant Johan Embrechts, Rhalid Akkari, Lieven Meerpoel
  • Patent number: 8314147
    Abstract: A compound of formula (I) or a pharmaceutically acceptable derivative thereof, wherein, R1, R2, R3, R4, R5, m, n and X are as defined in the specification; a process for preparing such compounds; a pharmaceutical composition comprising such compounds; and the use of such compounds in medicine.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: November 20, 2012
    Assignee: Glaxo Group Limited
    Inventors: Alessandra Gaiba, Mark Patrick Healy, Christopher Norbert Johnson, Susan Roomans, Steven James Stanway, Martin Edward Swarbrick
  • Patent number: 8236947
    Abstract: Disclosed are quinoline compounds having affinity for the 5-HT6 receptor and having the formula: where R1, R2, R3, R4, R5, n, m, p and A are defined herein, and salts thereof, compositions containing these compounds and salts and processes for making and using the same.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: August 7, 2012
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, Christopher Norbert Johnson, Martin C Jones, Gregor James MacDonald, Stephen Frederick Moss, Mervyn Thompson, Charles Edward Wade, David R Witty
  • Patent number: 8222245
    Abstract: The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: July 17, 2012
    Assignee: Glaxo Group Limited
    Inventors: Emmanuel Hubert Demont, Jag Paul Heer, John Skidmore, Ian David Wall, Jason Witherington, Thomas Daniel Heightman, David Nigel Hurst, Christopher Norbert Johnson
  • Publication number: 20110237792
    Abstract: Disclosed are quinoline compounds having affinity for the 5-HT6 receptor and having the formula: where R1, R2, R3, R4, R5, n, m, p and A are defined herein, and salts thereof, compositions containing these compounds and salts and processes for making and using the same.
    Type: Application
    Filed: June 3, 2011
    Publication date: September 29, 2011
    Inventors: Mahmood AHMED, Christopher Norbert Johnson, Martin C. Johnes, Gregor James MacDonald, Stephen Frederick Moss, Mervyn Thompson, Charles Edward Wade, David R. Witty
  • Patent number: 7977337
    Abstract: Disclosed are quinoline compounds having affinity for the 5-HT6 receptor and having the formula: where R1, R2, R3, R4, R5, n, m, p and A are defined herein, and salts thereof, compositions containing these compounds and salts and processes for making and using the same.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: July 12, 2011
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, Christopher Norbert Johnson, Martin C Jones, Gregor James MacDonald, Stephen Frederick Moss, Mervyn Thompson, Charles Edward Wade, David R Witty
  • Patent number: 7960563
    Abstract: The present invention relates to novel indazole derivatives having pharmacological activity, processes for their preparation, compositions containing them and uses of these compounds in the treatment of estrogen receptor beta mediated diseases.
    Type: Grant
    Filed: March 5, 2008
    Date of Patent: June 14, 2011
    Assignee: Glaxo Group Limited
    Inventors: Christopher Norbert Johnson, David G Jones, Xi Liang, David Timothy MacPherson, Aaron B Miller, Antoinette Naylor, Steven James Stanway, Andrew Kenneth Takle, Giancarlo Trani
  • Patent number: 7956083
    Abstract: The present invention relates to novel indole derivatives having pharmacological activity, processes for their preparation, compositions containing them and the use of these compounds in the treatment of estrogen receptor beta mediated diseases.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: June 7, 2011
    Assignee: Glaxo Group Limited
    Inventors: Christopher Norbert Johnson, David G. Jones, Xi Liang, David Timothy MacPherson, Aaron B Miller, Steven James Stanway, Andrew Kenneth Takle, Giancarlo Trani, Antoinette Wilson